Clinical Trial

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Study acronym: EVOKE-SCLC-04
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).
Protocol Amendment History 3 changes
notable Trial sites expanded: 210 -> 218 locations 2026-06-25
notable Trial sites expanded: 205 -> 210 locations 2026-05-21
critical Primary endpoint(s) modified 2026-04-30
Trial Details
NCT Number NCT06801834
Lead Sponsor Gilead Sciences
Conditions Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment 695 participants
Start Date 2025-04-04
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-12